ASTRAZEN inverted head and shoulder pattern

ASTRAZEN inverted head and shoulder pattern,

AstraZeneca Pharma India Limited financials summary for FY 2025:

Annual Revenue (Net): ₹1,713.29 crore (up from ₹1,295.53 crore in FY 2024)

Total Revenue: ₹1,756.92 crore

Profit Before Tax (PBT): ₹156.36 crore

Profit After Tax (PAT): ₹115.74 crore

Earnings Per Share (EPS): ₹46.30 (Basic and Diluted)

Major cost components include materials consumed (₹287.13 crore) and employee expenses (₹257.44 crore)

Finance cost is low, around ₹1.46 crore

The company has shown consistent profit growth over recent years with a 5-year CAGR of around 19.4%

Equity dividend rate for FY 2025 was 1,600% of the face value

The company is almost debt-free and reported steady margin improvement

AstraZeneca Pharma India is financially healthy with substantial revenue growth, profitability, and strong earnings per share backed by pharmaceutical operations in India. The company continues to focus on specialty medicine and oncology segments, driving steady business expansion.